1.	Phase I/II Study of Cetuximab and Recombinant Interleukin-12 in Patients With Unresectable Primary, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-11010, 11010, 8860, 2011C0019, NCT01468896
2.	Phase II Randomized Study of Multipeptide Vaccination Comprising Recombinant MAGE-3.1 Antigen, MART-1 Antigen, gp100 Antigen, and NA17-A2 Peptide Vaccines Emulsified With Montanide ISA-51 With Versus Without Recombinant Interleukin-12 Followed by Daclizumab in Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10-324-B, 10-324-B, 8445, NCT01307618